scholarly journals Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report

2019 ◽  
Vol Volume 12 ◽  
pp. 443-447 ◽  
Author(s):  
Zhan Wang ◽  
Wei-Ping Dai ◽  
Yuan-Sheng Zang
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Metastatic Colorectal Cancer ◽  
Complete Response ◽  
Egfr Inhibitor

scholarly journals Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report

2016 ◽  
Vol 13 (2) ◽  
pp. 979-983
Author(s):  
Morena Fasano ◽  
Alessio Fabozzi ◽  
Guido Giordano ◽  
Filippo Venturini ◽  
Gaetano Aurilio ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Elderly Patient ◽  
Case Report ◽  
Metastatic Colorectal Cancer ◽  
Frail Elderly ◽  
Complete Response ◽  
Frail Elderly Patient

scholarly journals The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report

2020 ◽  
Vol Volume 13 ◽  
pp. 11849-11853
Author(s):  
Zhan Wang ◽  
Chen-Yang Ye ◽  
Wen-Li Zhou ◽  
Miao-Miao Wang ◽  
Wei-Ping Dai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Metastatic Colorectal Cancer ◽  
Braf V600e ◽  
Combination Therapies

scholarly journals BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report

2019 ◽  
Vol 12 (2) ◽  
pp. 426-429
Author(s):  
Laure Moisset ◽  
Judith Raimbourg ◽  
Sandrine Hiret ◽  
Jonathan Dauve ◽  
Michèle Boisdron-Celle ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Lymph Node ◽  
Metastatic Colorectal Cancer ◽  
Peritoneal Carcinomatosis ◽  
Young Patient ◽  
Clinical Features ◽  
Short Review ◽  
Tumor Control

We report the case of a 32-year-old man with a caecal adenocarcinoma with major lymph node extension and peritoneal carcinomatosis, presenting a BRAF-K601E mutation. A triplet (5FU plus oxaliplatin plus irinotecan) combination with bevacizumab achieved tumor control but the disease progressed immediately after cessation and the patient died 8 months after the diagnosis. A short review of BRAF non-V600E mutations shows that outcome and clinical features depend on the mutation.

scholarly journals Fatal Type B Lactic Acidosis Associated With Metastatic Colorectal Cancer: A Case Report With Review of Literature, Pathogenesis, and Treatment

2018 ◽  
Vol 6 ◽  
pp. 232470961878810 ◽  
Author(s):  
Bharatsinh Gharia ◽  
Karan Seegobin ◽  
Hetavi Mahida ◽  
Marwan Shaikh ◽  
Trevanne Matthews Hew ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Lactic Acidosis ◽  
Metastatic Colorectal Cancer ◽  
Review Of Literature ◽  
Type B

Clinical Evidence of Regorifenib in Metastatic Colorectal Cancer: A Case Report

2019 ◽  
Vol 12 (2) ◽  
pp. 513
Author(s):  
K. Sukanya Mathew ◽  
Anjana Thomas ◽  
P R Roshni ◽  
Akhila Sivadas ◽  
K Pavithran
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Metastatic Colorectal Cancer ◽  
Clinical Evidence

Effect of PSK on FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 596-596
Author(s):  
M. Shibata ◽  
T. Shimura ◽  
K. Gonda ◽  
I. Nakamura ◽  
S. Ohki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Bone Marrow ◽  
Adverse Effects ◽  
Metastatic Colorectal Cancer ◽  
Progressive Disease ◽  
Complete Response ◽  
Bone Marrow Suppression ◽  
Published Data ◽  
Pulmonary Cancer ◽  
Cold Sensitive

596 Background: FOLFOX4 has been confirmed as an effective treatment for metastatic colorectal cancer and is used as a postoperative adjuvant therapy. However adverse effects such as cold-sensitive paresthesia and bone marrow suppression are common and may necessitate changes in chemotherapy regimen despite FOLFOX effectiveness. PSK, a polysaccharide derived from a species of mushroom, has been developed in Japan as an immune-enhancing agent and is widely used in patients with gastric, colorectal and pulmonary cancer. PSK has also been reported to decrease some adverse effects of chemotherapy. Methods: FOLFOX4 combined with PSK was administered to patients with metastatic colorectal cancer and the results were evaluated. Eight cycles of FOLFOX4 and PSK (3.0 g/day, p.o.) were given to 25 patients with metastatic colorectal cancer (19 hepatic, 3 pulmonary and 3 peritoneal). Results: No patients showed CR (complete response, 0%) while PR (partial response), SD (stable disease) and PD (progressive disease) were seen in 48%, 36% and 16% of patients, respectively. Response rate was 48% and disease control rate was 84%. Frequency of adverse effects was significantly lower than described in the published data. Grades 1 and 3 neutropenia occurred in 48% and 24% of patients, respectively; grades 1 and 3 nausea in 48% and 4%, respectively; and grades 1, 2 and 3 sensory neurotoxicity in 52%, 4% and 0%, respectively. No patient dropped out due to adverse effects in this study. Conclusions: PSK plus FOLFOX4 seems as effective as FOLFOX4 monotherapy, and significantly less toxic. These results suggest that this combination therapy may be more effective when given for a longer period, with lower incidence of adverse effects. No significant financial relationships to disclose.

Oxaliplatin rechallenge in patients with metastatic colorectal cancer prior treatment with oxaliplatin.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 785-785
Author(s):  
Jeong-Eun Kim ◽  
Yong Sang Hong ◽  
Kyu-Pyo Kim ◽  
Seong Joon Park ◽  
Jae-Lyun Lee ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hypersensitivity Reaction ◽  
Metastatic Colorectal Cancer ◽  
Treatment Option ◽  
Performance Status ◽  
Progression Free Survival ◽  
Complete Response ◽  
Cytotoxic Agents ◽  
Free Survival ◽  
Disease Free

785 Background: With limited number of available cytotoxic agents for the treatment of metastatic colorectal cancer (mCRC) patients (pts), rechallenge of chemotherapy can be considered for continuum of treatment. We investigated the efficacy and feasibility of oxaliplatin rechallenge in mCRC pts who have been already exposed to prior oxaliplatin-based chemotherapy. Methods: mCRC pts, who were re-treated with oxaliplatin-based chemotherapy as second or later line treatment in the presence of evaluable disease, were retrospectively accrued. Only those who remained disease-free or progression-free at least 6 months after the last dose of prior oxaliplatin were included. Results: Between January 2009 and May 2014, 110 pts were retreated with oxaliplatin-based regimen; 42 (38.2%) patients received prior oxaliplatin as adjuvant chemotherapy and 68 (61.8%) as palliative chemotherapy. Median disease-free or progression-free duration after prior oxaliplatin was 15.4 months (range, 12.9-17.6 months). All of them received oxaliplatin rechallenge in combination with fluoropyrimidines. The overall response rate to the oxaliplatin rechallenge was 30.9% (34/110), and the disease-control rate was 68.2% (75/110) with 1 complete response, 33 partial responses, and 41 stable diseases. Median progression-free survival and overall survival with rechallenge of oxaliplatin-based therapy were 5.9 months (95% CI, 4.6-7.2 months) and 19.7 months (95% CI, 11.9-27.5 months), respectively. Grade 2 or 3 neuropathy was observed in 16 patients. Any grade hypersensitivity reaction was observed in 10 patients within 4 cycle of treatment. Among them, 6 patients stopped treatment due to grade 3 or 4 hypersensitivity reaction. Conclusions: Rechallenge of oxaliplatin-based therapy could be a treatment option in patients who achieved at least 6 months of disease-free or progression-free survival with prior oxaliplatin-based chemotherapy, especially in those who have lack of further treatment option with good performance status. However, neurotoxicity and hypersensitivity reaction should be cautiously monitored in this setting.

Sign in / Sign up

Export Citation Format

Share Document